Development and Validation of a Vascular Endothelial Growth Factor A-associated Prognostic Model for Unresectable Hepatocellular Carcinoma
Kun He,Xinyu Liu,Zelong Yang
DOI: https://doi.org/10.2147/JHC.S399299
2023-02-05
Journal of Hepatocellular Carcinoma
Abstract:Kun He, &ast Xinyu Liu, &ast Zelong Yang Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zelong Yang, Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, No. 15, Changle West Road, Xi'an, People's Republic of China, Tel +86 17795714179, Email Purpose: High serum vascular endothelial growth factor (VEGF) levels have been identified as an independent risk factor for hepatocellular carcinoma (HCC). We aimed to construct a VEGF-included prognostic model to accurately perform individualized predictions of survival probability for patients with unresectable HCC. Patients and Methods: From October 2018 to March 2021, 182 consecutive newly diagnosed patients with unresectable HCC were retrospectively enrolled. Baseline serum VEGF-A and other characteristics were collected for all patients. Univariate Cox regression analysis and LASSO regression model were applied to develop the prognostic model, enhanced bootstrap method with 100 replicates was performed to validate its discrimination and calibration. We compared the final model with China Liver Cancer (CNLC) stage, American Joint Committee on Cancer (AJCC) stage, Barcelona Clinic Liver Cancer (BCLC) stage, and the model without the "VEGF". Finally, the established model was stratified by age. Results: The VEGF-associated prognostic model we established has high accuracy with an overall C-index of 0.7892 after correction for optimistic estimates. The area under the curve (AUC) of the time-dependent receiver operating characteristic (ROC) curves at 6-month, 1-year, and 2-year after correction were 0.843, 0.860, 0.833, respectively, and the calibration of the model was 0.1153, 0.1514, and 0.1711, respectively. The final model showed significant improvement in predicting OS when compared to the other models according to Harrell's C-index, The AUC of the time-dependent ROC, area under the decision curve analysis (AUDC), integrated discrimination improvement (IDI), and continuous net reclassification index (NRI). Conclusion: The VEGF-associated prognostic model may help to predict the survival probabilities of HCC patients with favorable performance and discrimination. However, further validation is required since we only verified this model using internal but not external data. Keywords: prognostic model, hepatocellular carcinoma, vascular endothelial growth factor, transcatheter arterial chemoembolization, sorafenib Liver cancer is the second leading cause of cancer-related mortality worldwide, and the most common type is hepatocellular carcinoma (HCC). 1,2 The 5-year survival rate for HCC patients is below 50% because of delayed diagnosis, postoperative recurrence, and distant metastasis. 3 Most patients with HCC are initially diagnosed at the advanced stage, leading to an inability to perform surgical resection. 4,5 Transcatheter arterial chemoembolization (TACE) was recommended as the standard therapy for patients with intermediate-stage HCC according to the guidelines of the European Association for the Study of Liver (EASL) and the American Association for the Study of Liver Disease (AASLD). 6,7 Regrettably, the median overall survival (OS) for these patients varies widely and ranges from 13 to 43 months, 8 at the same time, patients with poor local control after receiving TACE had a significant decrease in OS, so satisfactory therapeutic results cannot be achieved. 9 Hence, investigators have tried to combine TACE with other treatment modalities to increase the survival benefit for patients with advanced HCC. Sorafenib, an oral multikinase inhibitor, which targets multiple receptor tyrosine kinases including platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR), has been proven to improve the survival of patients with advanced HCC significantly. 10,11 However, sorafenib-related adverse events and resistance diminish its survival benefits. 12 A similar situation also occurred when patients received regorafenib. 13 Previous studies found that serum VEGF levels increased in HCC patients after the TACE procedure. 14,15 In addition, elevations in circulating VEGF were related to poor prognosis in patients with HCC. 16 Thus, the researchers compared the survival benefit of TACE plus sorafenib and TACE monotherapy in patients with advanced HCC. Some studies have suggested that the combination therapy of TACE-Sorafenib significantly prolongs the OS of patients compared with TACE alone. 17–21 Yet two -Abstract Truncated-
oncology